Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 45,984

Document Document Title
WO/2014/029102
The present invention relates to a thiazine amide derivative and a pharmaceutical use thereof, and particularly to a compound of formula I (in the formula, variables are as described in the specification), a pharmaceutically acceptable s...  
WO/2014/026330
The present invention relates to compounds according to Formula (I) or a pharmaceutically acceptable salt or solvate thereof. Such compounds can be used in the treatment of RORgammaT-mediated diseases or conditions.  
WO/2014/028829
The invention provides novel ligands of Kappa (κ) opioid receptors, such as can be used to modulate a Kappa opioid receptor. Methods of synthesis and methods of use are also provided. Compounds of the invention can be used therapeutical...  
WO/2014/026880
The present invention relates to ethynyl derivatives of formula I wherein R1 is hydrogen or halogen; R2 is C1-3-alkyl or -(CH2)m-O-CH3; n is 2 or 3; m is 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixtur...  
WO/2014/028587
The present disclosure relates to nanosized chitosan-statin conjugates, nanosized chitosan-chemotherapeutic agent conjugates, compositions comprising such nanosized chitosan-drug conjugates, and methods of making and using the same. The ...  
WO/2014/028883
The present invention is directed to novel treatment of controlling hippocampal neural circuit hyperexcitability occurring in a neurological disease or disorder associated with epileptogenesis in a subject in need of such treatment, comp...  
WO/2014/026341
Disclosed is an oral drug or health food which main components comprise ginsenoside (Rg1+Rb1+Re), glycyrrhetic acid and chinese date cAMP for increasing content and availability of cAMP in vivo rapidly.  
WO/2014/028800
Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, ring A, and G are defined her...  
WO/2014/026557
The present invention provides a use of 3-amino-1-propanesulfonic acid and derivatives thereof in manufacture of medicaments for the treatment of cardiovascular and cerebrovascular diseases or neurodegenerative diseases. 3-amino-1-propan...  
WO/2014/027885
This invention pertains to the use of an uridine source, preferably uridine monophosphate,for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8μM in a subject in need thereof, comprisi...  
WO/2014/028387
Disclosed herein is use of one or more aminopyridines in methods and compositions for improving walking capacity in patients with multiple sclerosis.  
WO/2014/027668
[Problem] To identify an enzyme that decomposes active reelin into an inactive form and to provide an effective treatment and research means for diseases such as Alzheimer's disease based on active reelin decrease using this enzyme and/o...  
WO/2014/027023
The present invention is directed to compositions, preferably dietetic compositions suitable for the treatment of malnutrition, in the treatment of neurological diseases, particularly epilepsy and related diseases such as difficult-to-co...  
WO/2014/027882
This invention pertains to the use of an uridine source, preferably uridine monophosphate,for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 µM in a subject in need thereof, compris...  
WO/2014/028479
The present invention provides compounds of Formula (I) that are GPR6 modulators and are therefore useful for the treatment of diseases treatable by modulation of GPR6, in particular treating Parkinson disease, levodopa induced dyskinesi...  
WO/2014/028868
This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally administering to the subject a controlled release fo...  
WO/2014/028399
This invention provides a method of treating a human subject suffering from a CB1 receptor related disorder comprising periodically administering to the subject an effective amount of laquinimod or pharmaceutically acceptable salt thereo...  
WO/2014/026881
The invention relates to imidazo[2,1-b]thiazol-3-one derivatives of formula (I) wherein the variables are as defined in the claims. It has been shown that the present compounds may be used for binding and imaging tau aggregates and relat...  
WO/2014/026372
Disclosed is a pharmaceutical composition for inhibiting autophagy of motor neurons containing an effective amount of an active ingredient. The active ingredient is selected from the following groups: a compound of formula (I), pharmaceu...  
WO/2014/024984
The purpose of the present invention is to provide a hydrogen mixed gas supply device capable of administering a mixed gas having the hydrogen gas concentration and the oxygen gas concentration thereof each appropriately adjusted in acco...  
WO/2014/026121
A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carr...  
WO/2014/023390
Compounds of the formula (I), in which R1, X, Y and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central ne...  
WO/2014/024125
Pyrazolo[4,3-d]pyrimidin-7(6H)-one derivatives represented by the general formula (I), wherein R1 represents hydrogen atom or methyl; when R1 represents hydrogen atom, then R2 represents cyclopentyl, tetrahydropyranyl, cyclohexyl, or cyc...  
WO/2014/025837
Compositions and methods of treatment of tauopathies are provided. In some embodiments, an antagonist of endothelin receptor A (ETA) and endothelin receptor B (ETB) may be administered to a subject to reduce tau production or accumulatio...  
WO/2014/025761
The present invention is based on the discovery that motor neurons derived from patients with a neurodegenerative disease have decreased delayed rectifier potassium current and increased persistent sodium current compared to motor neuron...  
WO/2014/023129
Provided are a new α-conotoxin peptide, and a medical composition and a purpose thereof. Further provided are a propeptide, a nucleic acid construct, an expression vector, a transformed cell and a fusion protein of the conotoxin peptide...  
WO/2014/025808
Provided herein are curcumin analogues that are able to interact with amyloid β (Aβ) and to attenuate the copper-induced crosslinking of Aβ. Also provided herein are methods of using the compounds in the treatment of Alzheimer's Disea...  
WO/2014/025679
The present invention is directed to a process for the preparation of heterocyclic derivatives of formula I (I), wherein J, X, Z, W and R2 are as defined herein using a palladium catalysed aminocarbonylation reaction. Such compounds are ...  
WO/2014/025993
D-amino acid oxidase (DAAO) inhibitors and methods of their use, either alone or in combination with D-serine or D-alanine, to facilitate allosteric activation of NMDA receptor-mediated neurotransmission and methods of their use as thera...  
WO/2014/022879
The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment...  
WO/2014/025019
Provided is a means for improving breeding performance of industrial animals. This animal feed is provided to industrial animals to raise the industrial animals, and is characterized by containing L-valine and L-lysine, and having a mass...  
WO/2014/025202
The present invention relates to a pharmaceutical composition or a functional food composition comprising a mixed extract of Zingiber officinale ROSC and Paeonia lactiflora Pallas as an active ingredient for preventing or treating dement...  
WO/2014/023860
The aim of the invention is the treatment of neurodegenerative diseases or other applicable pathologies by means of the intranasal application of a composition obtained from at least one blood compound and having growth factors, or by me...  
WO/2014/025905
In certain embodiments multi-component formulations are provided where the formulations comprise a first component comprising one or more vitamins selected from the group consisting of one or more B vitamins, vitamin C, vitamin D, vitami...  
WO/2014/026164
There are dynamic interdependence and complex signaling between all of the brain's cellular elements such as glia and especially oligodendrocytes. The evidence suggests that aspects of the human brain such as myelin and the homeostatic r...  
WO/2014/025942
This disclosure relates to NMDA modulators and used related thereto such as for treatment of central nervous system disorders. In certain embodiments, compounds disclosed herein are NR2C subunit-selective NMDA potentiators. In certain em...  
WO/2014/025651
Chroman compounds and derivatives of Formula (I) are useful inhibitors of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical composit...  
WO/2014/023191
Disclosed are an N-substituted pyrazolo [3, 4-d] pyrimidine ketone compound, a preparation method therefore and application thereof as an inhibitor for phosphodiesterase IX (PDEIX). In Formula (I), R' is selected from isopropyl, cyclopen...  
WO/2014/023674
The present invention relates to compounds of general formula (I), wherein R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkoxy substituted by halogen or cyano; R2 is hydrogen, lower alkyl or lower alkyl substituted by haloge...  
WO/2014/024993
Provided is a compound having an antagonistic activity on an arginine-vasopressin 1b receptor. A compound represented by general formula (I) [wherein each symbol is as defied in the description] or a salt thereof has an antagonistic acti...  
WO/2014/023385
Compounds of the formula (I) in which R, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of Syk, and can be employed, inter alia, for the treatment of cancer, rheumatoid arthritis and / or systemic lupus  
WO/2014/025905
In certain embodiments multi-component formulations are provided where the formulations comprise a first component comprising one or more vitamins selected from the group consisting of one or more B vitamins, vitamin C, vitamin D, vitami...  
WO/2014/023390
Compounds of the formula (I), in which R1, X, Y and n have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central ne...  
WO/2014/020405
The disclosure relates to Cyclic Urea- or Lactam-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein R1, R2, Qa, Y1, Z, A, B, Qx, E, G, J, M, U, W, and a are as de...  
WO/2014/021393
The present invention relates to a transdermal absorption-type pharmaceutical preparation having improved zonisamide cutaneous permeation. This transdermal absorption-type pharmaceutical preparation is characterized by containing (i) zon...  
WO/2014/020480
The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount ...  
WO/2014/019268
A pharmaceutical composition for promoting nerve injury restoration and an application thereof. The pharmaceutical composition in each unit contains 0.5-8g of L-ornithine, 1-5g of aspartic acid, 3-10g of arginine, and 3-10g of vitamin B6...  
WO/2014/019023
The present invention relates to chemical compounds of formula (I), with the substituents as described in the specification, useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR). The invention als...  
WO/2014/022570
An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition comprises a multiparticulate modified releas...  
WO/2014/022340
This invention relates the use of Cortisol blockers (glucocorticoid receptor [GR] antagonists) for the prevention or addiction induced anxiety and withdrawal side effects as a therapeutic and in concert with a diagnostic. Such addictions...  

Matches 451 - 500 out of 45,984